CHAPTERS
- Promising pipeline ensures mid- and long-term innovation
  
  Click here to go the chapters directly:
  
  Balanced mix of new substance developments and life cycle management opportunities
  
  Pipeline overview
LINKS
- Research and Development
  
  More information about the topic Research and Development:
  
  News
  
  Facts & Figures
  
  Research Areas
  
  The Lab Tour – From molecules to medicine
  
  Innovation & Ethics
  
  Clinical studies
  
  Contact Research Form
  
  Please choose our email contact form
Printer friendly version
Bookmark this page
gross

Promising pipeline ensures mid- and long-term innovation

Bayer Schering Pharma concentrates its R&D activities on innovative treatment alternatives for diseases with a high unmet medical need to improve patients’ quality of life and prolong lives. The focus is on therapeutic areas with a high medical need, where more innovations are needed despite considerable progress.

Balanced mix of new substance developments and life cycle management opportunities

In this context, Bayer Schering Pharma focuses on its core competencies and its many years of experience. We thus hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology. With new approaches in cancer therapy, cardiovascular diseases, gynaecological therapies and molecular imaging Bayer Schering Pharma seeks to become an innovation leader in these fields.

In addition, Bayer Schering Pharma is further developing currently marketed products in order to improve their application and/or extend the range of indications.

Pipeline overview

The following table sets forth our development projects, their business unit, their indication as well as their development status.

Here you can find an overview on our development pipeline. more

*NME = New molecular entity
LCM = Life Cycle Management